EXPERIENCE WITH TOFACINITIB AND BARICITINIB IN RHEUMATOID ARTHRITIS

5PSQ-056

https://www.eahp.eu/25-5PSQ-056

[1] MI Bernias Domínguez, [1]M Mañes Sevilla, [2]PM Bernias Domínguez, [1]L Corrales Pérez, [1]I Sollano Sancho, [1]I Morona Minguez, [1]J Solis Olivares, [1]C Moriel Sánchez .

[1] *Department of Hospital Pharmacy*. HOSPITAL UNIVERSITARIO DE MÓSTOLES (Madrid)

[2]*Medical Department*. FREMAP Torrejón de Ardoz (Madrid)

Contact: miriamisabel.bernias@salud.madrid.org

ATC code: L04 – Immunosuppressive agents

BACKGROUND

Tofacitinib and baricitinib were recently approved for rheumatoid arthritis (RA) treatment.
This was a breakthrough because of their oral administration and new mechanism of action.

AIM AND OBJECTIVES

To analyse tofacitinib and baricitinib treatment for RA and adverse effects (AE) after starting treatment in a second level hospital.

MATERIALS AND METHODS

Retrospective observational study was conducted in all patients starting baricitinib and tofacitinib treatment until September 2019.



RESULTS

N= 47

26 Baricitinib
21 Tofacitinib

12.8% men
57±12.6 year

100% had recived any DMARD

55.3% had received any biologic agent

24 Eas detected
15 Patients (31,9%)

8 patients with Baricitinib; 15 EAs

7 patients with Tofacitinib; 11 EAs

Treatment suspension

6 Baricitinib
- 4 for EAs
- 2 for non improvement

4 Tofacitinib
- 0 for EAs
- 4 for non improvement





CONCLUSIONS

The population that started treatment with tofacitinib and baricitinib were mostly middle aged women with at least one previous treatment with DMARD. More than half of the patients had received some biologic previously.
In spite of the limitations of this study (probable underestimation of AEs), tofacitinib and baricitinib showed an **acceptable profile of adverse reactions**, similar to those described on both technical data sheets.